AR127488A1 - Inhibidores de la proteína que contiene el dominio de prolil hidroxilasa (phd) y usos de los mismos - Google Patents
Inhibidores de la proteína que contiene el dominio de prolil hidroxilasa (phd) y usos de los mismosInfo
- Publication number
- AR127488A1 AR127488A1 ARP220102935A ARP220102935A AR127488A1 AR 127488 A1 AR127488 A1 AR 127488A1 AR P220102935 A ARP220102935 A AR P220102935A AR P220102935 A ARP220102935 A AR P220102935A AR 127488 A1 AR127488 A1 AR 127488A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- nrcrd
- heterocycloalkyl
- cycloalkyl
- heteroaryl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 102000004079 Prolyl Hydroxylases Human genes 0.000 title 1
- 108010043005 Prolyl Hydroxylases Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 19
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 18
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 18
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 17
- 125000001072 heteroaryl group Chemical group 0.000 abstract 17
- 125000003118 aryl group Chemical group 0.000 abstract 16
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 15
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 abstract 15
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 15
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 15
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract 9
- 239000001257 hydrogen Substances 0.000 abstract 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 9
- 229910052736 halogen Inorganic materials 0.000 abstract 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 7
- 125000003342 alkenyl group Chemical group 0.000 abstract 6
- 150000002367 halogens Chemical group 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000004429 atom Chemical group 0.000 abstract 5
- 125000000304 alkynyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 125000001246 bromo group Chemical group Br* 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- HKIOYBQGHSTUDB-UHFFFAOYSA-N folpet Chemical group C1=CC=C2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C2=C1 HKIOYBQGHSTUDB-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En la presente se describen inhibidores de PHD y composiciones farmacéuticas que comprenden estos inhibidores. Los compuestos y composiciones de la presente son útiles para el tratamiento de una enfermedad o trastorno asociado con PHD. Reivindicación 1: Un compuesto de la fórmula (1), o una sal farmacéuticamente aceptable, o estereoisómero del mismo, en donde: R¹ es hidrógeno, halógeno, -W-CN, -W-NO₂, -OH, -W-ORᵃ, -W-OC(=O)Rᵃ, -W-OC(=O)ORᵇ, -W-OC(=O)NRᶜRᵈ, -W-SH, -W-SRᵃ, -W-S(=O)Rᵃ, -W-S(=O)₂Rᵃ, -W-S(=O)₂NRᶜRᵈ, -W-NRᶜRᵈ, -W-NRᵇC(=O)NRᶜRᵈ, -W-NRᵇC(=O)Rᵃ, -W-NRᵇC(=O)ORᵇ, -W-NRᵇS(=O)₂Rᵃ, -W-C(=O)Rᵃ, -W-C(=O)ORᵇ, -W-C(=O)NRᶜRᵈ, C₁-C₆ alquilo, C₁-C₆ haloalquilo, C₁-C₆ hidroxialquilo, C₁-C₆ aminoalquilo, C₁-C₆ heteroalquilo, C₂-C₆ alquenilo, C₂-C₆ alquinilo, cicloalquilo, heterocicloalquilo, arilo, heteroarilo, C₁-C₆ alquileno(cicloalquilo), C₁-C₆ alquileno(heterocicloalquilo), C₁-C₆ alquileno(arilo) o C₁-C₆ alquileno(heteroarilo); en donde el alquilo, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, arilo y heteroarilo están opcionalmente e independientemente sustituidos con uno o más R¹ᵃ; cada R¹ᵃ es independientemente halógeno, -CN, -NO₂, -OH, -ORᵃ, -OC(=O)Rᵃ, -OC(=O)ORᵇ, -OC(=O)NRᶜRᵈ, -SH, -SRᵃ, -S(=O)Rᵃ, -S(=O)₂Rᵃ, -S(=O)₂NRᶜRᵈ, -NRᶜRᵈ, -NRᵇC(=O)NRᶜRᵈ, -NRᵇC(=O)Rᵃ, -NRᵇC(=O)ORᵇ, -NRᵇS(=O)₂Rᵃ, -C(=O)Rᵃ, -C(=O)ORᵇ, -C(=O)NRᶜRᵈ, C₁-C₆ alquilo, C₁-C₆ haloalquilo, C₁-C₆ hidroxialquilo, C₁-C₆ aminoalquilo, C₁-C₆ heteroalquilo, C₂-C₆ alquenilo, C₂-C₆ alquinilo, cicloalquilo, heterocicloalquilo, arilo o heteroarilo; o dos R¹ᵃ en el mismo átomo se toman conjuntamente para formar un oxo; W está ausente o C₁-C₆alquileno; X es N o CR²; R² es hidrógeno, fluoro, cloro, bromo, -CN, -NO₂, -OH, -ORᵃ, -C(=O)Rᵃ, -C(=O)ORᵇ, -C(=O)NRᶜRᵈ, C₁-C₆ alquilo, C₁-C₆ haloalquilo, C₁-C₆ hidroxialquilo, C₁-C₆ aminoalquilo o C₁-C₆ heteroalquilo; R³ es hidrógeno, halógeno, -CN, -NO₂, -OH, -ORᵃ, -C(=O)Rᵃ, -C(=O)ORᵇ, -C(=O)NRᶜRᵈ, C₁-C₆ alquilo, C₁-C₆ haloalquilo, C₁-C₆ hidroxialquilo, C₁-C₆ aminoalquilo o C₁-C₆ heteroalquilo; R⁴ es hidrógeno, halógeno, -CN, -NO₂, -OH, -ORᵃ, -C(=O)Rᵃ, -C(=O)ORᵇ, -C(=O)NRᶜRᵈ, C₁-C₆ alquilo, C₁-C₆ haloalquilo, C₁-C₆ hidroxialquilo, C₁-C₆ aminoalquilo o C₁-C₆ heteroalquilo; R⁵ es hidrógeno, C₁-C₆ alquilo, C₁-C₆ haloalquilo, C₁-C₆ hidroxialquilo, C₁-C₆ aminoalquilo o C₁-C₆ heteroalquilo; Y es -O-, -S- o -NR⁶-; R⁶ es hidrógeno, C₁-C₆ alquilo, C₁-C₆ haloalquilo, C₁-C₆ hidroxialquilo, C₁-C₆ aminoalquilo o C₁-C₆ heteroalquilo; L es -(CR⁷R⁸)ₚ-; cada R⁷ y R⁸ es independientemente hidrógeno, C₁-C₆ alquilo, C₁-C₆ haloalquilo, C₁-C₆ hidroxialquilo, C₁-C₆ aminoalquilo o C₁-C₆ heteroalquilo; o R⁷ y R⁸ en el mismo carbono se toman conjuntamente para formar un cicloalquilo o heterocicloalquilo; cada uno opcionalmente sustituido con uno o más R⁷ᵃ; cada R⁷ᵃ es independientemente halógeno, -CN, -NO₂, -OH, -ORᵃ, -NRᶜRᵈ, -C(=O)Rᵃ, -C(=O)ORᵇ, -C(=O)NRᶜRᵈ, C₁-C₆ alquilo, C₁-C₆ haloalquilo, C₁-C₆ hidroxialquilo, C₁-C₆ aminoalquilo o C₁-C₆ heteroalquilo; p es 0 - 4; El anillo A es cicloalquilo, heterocicloalquilo, arilo o heteroarilo; cada R⁹ es independientemente halógeno, -CN, -NO₂, -OH, -ORᵃ, -OC(=O)Rᵃ, -OC(=O)ORᵇ, -OC(=O)NRᶜRᵈ, -SH, -SRᵃ, -S(=O)Rᵃ, -S(=O)₂Rᵃ, -S(=O)₂NRᶜRᵈ, -NRᶜRᵈ, -NRᵇC(=O)NRᶜRᵈ, -NRᵇC(=O)Rᵃ, -NRᵇC(=O)ORᵇ, -NRᵇS(=O)₂Rᵃ, -C(=O)Rᵃ, -C(=O)ORᵇ, -C(=O)NRᶜRᵈ, C₁-C₆ alquilo, C₁-C₆ haloalquilo, C₁-C₆ hidroxialquilo, C₁-C₆ aminoalquilo, C₁-C₆ heteroalquilo, C₂-C₆ alquenilo, C₂-C₆ alquinilo, cicloalquilo, heterocicloalquilo, arilo o heteroarilo; en donde el alquilo, alquenilo, alquenilo, cicloalquilo, heterocicloalquilo, arilo y heteroarilo están opcionalmente e independientemente sustituidos con una o más R⁹ᵃ; o dos R⁹ en el mismo átomo se toman conjuntamente para formar un oxo; cada R⁹ᵃ es independientemente halógeno, -CN, -NO₂, -OH, -ORᵃ, -OC(=O)Rᵃ, -OC(=O)ORᵇ, -OC(=O)NRᶜRᵈ, -SH, -SRᵃ, -S(=O)Rᵃ, -S(=O)₂Rᵃ, -S(=O)₂NRᶜRᵈ, -NRᶜRᵈ, -NRᵇC(=O)NRᶜRᵈ, -NRᵇC(=O)Rᵃ, -NRᵇC(=O)ORᵇ, -NRᵇS(=O)₂Rᵃ, -C(=O)Rᵃ, -C(=O)ORᵇ, -C(=O)NRᶜRᵈ, C₁-C₆ alquilo, C₁-C₆ haloalquilo, C₁-C₆ hidroxialquilo, C₁-C₆ aminoalquilo, C₁-C₆ heteroalquilo, C₂-C₆ alquenilo, C₂-C₆ alquinilo, cicloalquilo, heterocicloalquilo, arilo o heteroarilo; o dos R⁹ᵃ en el mismo átomo se toman conjuntamente para formar un oxo; n es 0 - 4; cada Rᵃ es independientemente C₁-C₆ alquilo, C₁-C₆ haloalquilo, C₁-C₆ hidroxialquilo, C₁-C₆ aminoalquilo, C₁-C₆ heteroalquilo, C₂-C₆ alquenilo, C₂-C₆ alquinilo, cicloalquilo, heterocicloalquilo, arilo, heteroarilo, C₁-C₆ alquilen(cicloalquilo), C₁-C₆ alquilen(heterocicloalquilo), C₁-C₆ alquilen(arilo) o C₁-C₆ alquilen(heteroarilo); en donde cada alquilo, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, arilo y heteroarilo está independientemente opcionalmente sustituido con uno o más R; cada Rᵇ es independientemente hidrógeno, C₁-C₆ alquilo, C₁-C₆ haloalquilo, C₁-C₆ hidroxialquilo, C₁-C₆ aminoalquilo, C₁-C₆ heteroalquilo, C₂-C₆ alquenilo, C₂-C₆ alquinilo, cicloalquilo, heterocicloalquilo, arilo, heteroarilo, C₁-C₆ alquilen(cicloalquilo), C₁-C₆ alquilen(heterocicloalquilo), C₁-C₆ alquilen(arilo) o C₁-C₆ alquilen(heteroarilo); en donde cada alquilo, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, arilo y heteroarilo está independientemente, opcionalmente sustituido con uno o más R; cada Rᶜ y Rᵈ son independientemente hidrógeno, C₁-C₆ alquilo, C₁-C₆ haloalquilo, C₁-C₆ hidroxialquilo, C₁-C₆ aminoalquilo, C₁-C₆ heteroalquilo, C₂-C₆ alquenilo, C₂-C₆ alquinilo, cicloalquilo, heterocicloalquilo, arilo, heteroarilo, C₁-C₆ alquilen(cicloalquilo), C₁-C₆ alquilen(heterocicloalquilo), C₁-C₆ alquilen(arilo) o C₁-C₆ alquilen(heteroarilo); en donde cada alquilo, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, arilo y heteroarilo está independientemente, opcionalmente sustituido con uno o más R; o Rᶜ y Rᵈ se toman juntamente con el átomo al cual se unen para formar un heterocicloalquilo opcionalmente sustituido con uno o más R; y cada R es independientemente halógeno, -CN, -OH, -OC₁-C₆ alquilo, -S(=O)C₁-C₆ alquilo, -S(=O)₂C₁-C₆ alquilo, -S(=O)₂NH₂, -S(=O)₂NHC₁-C₆ alquilo, -S(=O)₂N(C₁-C₆ alquilo)₂, -NH₂, -NHC₁-C₆ alquilo, -N(C₁-C₆ alquilo)₂, -NHC(=O)OC₁-C₆ alquilo, -C(=O)C₁-C₆ alquilo, -C(=O)OH, -C(=O)OC₁-C₆ alquilo, -C(=O)NH₂, -C(=O)N(C₁-C₆ alquilo)₂, -C(=O)NHC₁-C₆ alquilo, C₁-C₆ alquilo, C₁-C₆ haloalquilo, C₁-C₆ hidroxialquilo, C₁-C₆ aminoalquilo, o C₁-C₆ heteroalquilo; o dos R en el mismo átomo se toman conjuntamente para formar un oxo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021127023 | 2021-10-28 | ||
| CN2022112270 | 2022-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127488A1 true AR127488A1 (es) | 2024-01-31 |
Family
ID=86159087
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102935A AR127488A1 (es) | 2021-10-28 | 2022-10-28 | Inhibidores de la proteína que contiene el dominio de prolil hidroxilasa (phd) y usos de los mismos |
| ARP220102948A AR127501A1 (es) | 2021-10-28 | 2022-10-28 | Inhibidores de la proteína que contiene el dominio de prolil hidroxilasa (phd) y usos de los mismos |
| ARP220102947A AR127500A1 (es) | 2021-10-28 | 2022-10-28 | Inhibidores de la proteína que contiene el dominio de prolil hidroxilasa (phd) y usos de los mismos |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102948A AR127501A1 (es) | 2021-10-28 | 2022-10-28 | Inhibidores de la proteína que contiene el dominio de prolil hidroxilasa (phd) y usos de los mismos |
| ARP220102947A AR127500A1 (es) | 2021-10-28 | 2022-10-28 | Inhibidores de la proteína que contiene el dominio de prolil hidroxilasa (phd) y usos de los mismos |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US11780854B2 (es) |
| EP (2) | EP4422623A1 (es) |
| KR (2) | KR20240095274A (es) |
| CN (2) | CN118591533A (es) |
| AR (3) | AR127488A1 (es) |
| AU (1) | AU2022378858A1 (es) |
| CA (1) | CA3235718A1 (es) |
| IL (1) | IL312220A (es) |
| TW (3) | TW202332677A (es) |
| WO (3) | WO2023072240A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023072240A1 (en) | 2021-10-28 | 2023-05-04 | Insilico Medicine Ip Limited | Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof |
| GB202301059D0 (en) | 2023-01-25 | 2023-03-08 | Univ Oxford Innovation Ltd | PHD inhibitors |
| CN117402178B (zh) * | 2023-12-15 | 2024-03-08 | 英矽智能科技(上海)有限公司 | 作为jak抑制剂和phd抑制剂的嘧啶类化合物 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6730682B2 (en) * | 2000-07-12 | 2004-05-04 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
| AU2003262946A1 (en) * | 2002-08-30 | 2004-03-19 | Pharmacia And Upjohn Company | Method of preventing or treating atherosclerosis or restenosis |
| US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| GB0505621D0 (en) * | 2005-03-18 | 2005-04-27 | Glaxo Group Ltd | Novel compounds |
| WO2009002533A1 (en) | 2007-06-27 | 2008-12-31 | The Brigham And Women's Hospital, Inc. | Inflammatory bowel disease therapies |
| US20110028507A1 (en) * | 2007-08-10 | 2011-02-03 | Crystalgenomics, Inc. | Pyridine derivatives and methods of use thereof |
| CN102858763B (zh) | 2010-02-23 | 2015-01-21 | 康奈尔大学 | 脯氨酰羟化酶抑制剂及其使用方法 |
| CN104470899B (zh) * | 2012-03-09 | 2017-12-26 | 菲布罗根有限公司 | 作为hif羟化酶抑制剂的4‑羟基‑异喹啉化合物 |
| GB201504565D0 (en) | 2015-03-18 | 2015-05-06 | Takeda Pharmaceutical | Novel compounds |
| CN106146490B (zh) | 2015-03-27 | 2018-10-23 | 沈阳三生制药有限责任公司 | 被芳氧基或杂芳氧基取代的5-羟基-1,7-萘啶化合物、其制备方法及其制药用途 |
| CN106146491B (zh) | 2015-03-27 | 2017-12-12 | 沈阳三生制药有限责任公司 | 被芳基或杂芳基取代的5‑羟基‑1,7‑萘啶化合物、其制备方法及其制药用途 |
| CN108341777A (zh) | 2017-01-23 | 2018-07-31 | 四川科伦博泰生物医药股份有限公司 | 异喹啉酮类化合物及其应用 |
| US10253018B2 (en) * | 2017-05-25 | 2019-04-09 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| TW201920108A (zh) * | 2017-09-25 | 2019-06-01 | 日商武田藥品工業有限公司 | N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物 |
| CN109575016B (zh) * | 2017-09-28 | 2022-01-04 | 药捷安康(南京)科技股份有限公司 | Pde9抑制剂及其用途 |
| CN110878096A (zh) | 2018-09-05 | 2020-03-13 | 石药集团中奇制药技术（石家庄）有限公司 | 一种1,7-萘啶类衍生物及其制备方法和用途 |
| CN112979541B (zh) | 2019-12-17 | 2022-11-11 | 浙江大学 | 一种基于n-(3-羟基吡啶-2-羰基)甘氨酸的抗肿瘤药物增敏剂及其应用 |
| MX2022010011A (es) * | 2020-02-12 | 2022-10-18 | Amgen Inc | Inhibidores de prmt5 novedosos. |
| GB202004960D0 (en) * | 2020-04-03 | 2020-05-20 | Kinsenus Ltd | Inhibitor compounds |
| WO2023072240A1 (en) * | 2021-10-28 | 2023-05-04 | Insilico Medicine Ip Limited | Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof |
-
2022
- 2022-10-28 WO PCT/CN2022/128220 patent/WO2023072240A1/en active Application Filing
- 2022-10-28 TW TW111141238A patent/TW202332677A/zh unknown
- 2022-10-28 TW TW111141004A patent/TW202334134A/zh unknown
- 2022-10-28 WO PCT/CN2022/128237 patent/WO2023072246A1/en unknown
- 2022-10-28 IL IL312220A patent/IL312220A/en unknown
- 2022-10-28 KR KR1020247017207A patent/KR20240095274A/ko unknown
- 2022-10-28 EP EP22886115.9A patent/EP4422623A1/en active Pending
- 2022-10-28 CN CN202280086996.5A patent/CN118591533A/zh active Pending
- 2022-10-28 CA CA3235718A patent/CA3235718A1/en active Pending
- 2022-10-28 AR ARP220102935A patent/AR127488A1/es unknown
- 2022-10-28 AU AU2022378858A patent/AU2022378858A1/en active Pending
- 2022-10-28 TW TW111141254A patent/TW202334158A/zh unknown
- 2022-10-28 AR ARP220102948A patent/AR127501A1/es unknown
- 2022-10-28 WO PCT/CN2022/128293 patent/WO2023072257A1/en active Application Filing
- 2022-10-28 EP EP22886132.4A patent/EP4423074A1/en active Pending
- 2022-10-28 AR ARP220102947A patent/AR127500A1/es unknown
- 2022-10-28 KR KR1020247017209A patent/KR20240093899A/ko unknown
- 2022-10-28 CN CN202280086990.8A patent/CN118488838A/zh active Pending
-
2023
- 2023-02-15 US US18/110,261 patent/US11780854B2/en active Active
- 2023-02-15 US US18/110,259 patent/US11731987B2/en active Active
- 2023-06-22 US US18/339,362 patent/US12071443B2/en active Active
- 2023-08-31 US US18/240,886 patent/US20240067661A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202334158A (zh) | 2023-09-01 |
| WO2023072246A1 (en) | 2023-05-04 |
| CN118488838A (zh) | 2024-08-13 |
| AR127500A1 (es) | 2024-01-31 |
| EP4422623A1 (en) | 2024-09-04 |
| KR20240093899A (ko) | 2024-06-24 |
| IL312220A (en) | 2024-06-01 |
| US20240002406A1 (en) | 2024-01-04 |
| US20240067661A1 (en) | 2024-02-29 |
| US20230192723A1 (en) | 2023-06-22 |
| CA3235718A1 (en) | 2023-05-04 |
| EP4423074A1 (en) | 2024-09-04 |
| US20230192688A1 (en) | 2023-06-22 |
| WO2023072240A1 (en) | 2023-05-04 |
| CN118591533A (zh) | 2024-09-03 |
| AR127501A1 (es) | 2024-01-31 |
| US11780854B2 (en) | 2023-10-10 |
| US11731987B2 (en) | 2023-08-22 |
| WO2023072257A1 (en) | 2023-05-04 |
| KR20240095274A (ko) | 2024-06-25 |
| AU2022378858A1 (en) | 2024-05-02 |
| TW202334134A (zh) | 2023-09-01 |
| US12071443B2 (en) | 2024-08-27 |
| TW202332677A (zh) | 2023-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR127488A1 (es) | Inhibidores de la proteína que contiene el dominio de prolil hidroxilasa (phd) y usos de los mismos | |
| AR119731A1 (es) | Inhibidores del inflamasoma nlrp3 | |
| AR116604A1 (es) | Inhibidores de kras g12c | |
| AR118205A1 (es) | Compuestos que tienen actividad inductora de ferroptosis | |
| AR109349A1 (es) | Compuestos y usos | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR088535A1 (es) | Derivados de amidas de aminoacidos sustituidos con n-urea como moduladores de receptor formil peptido del receptor del tipo 1 (fprl-1) | |
| AR125425A1 (es) | Inhibidores de proteina tirosina fosfatasa y sus metodos de uso | |
| AR128669A1 (es) | INHIBIDORES DE DIACILGLICEROL CINASA (DGK) a Y USOS DE LOS MISMOS | |
| AR106297A1 (es) | Compuestos macrocíclicos modificados como inhibidores selectivos de la quinasa cdk9 | |
| AR119019A1 (es) | Antibióticos macrocíclicos de amplio espectro | |
| AR102222A1 (es) | Compuestos de indolinona, composiciones farmacéuticas que los comprende y usos de los mismos | |
| CO2021017202A2 (es) | Compuestos tricíclicos | |
| AR128418A1 (es) | Inhibidores de la proteína tirosina fosfatasa y usos de estos | |
| AR128417A1 (es) | Inhibidores de la proteína tirosina fosfatasa y usos de estos | |
| AR113799A1 (es) | Derivados de alcoxiamino para tratar dolor y estados relacionados con dolor | |
| CL2022002106A1 (es) | Moduladores de nampt. | |
| AR125448A1 (es) | Moduladores de trex1 | |
| AR108671A1 (es) | Análogos de diamida imidodicarbonimidica | |
| AR088639A1 (es) | Composicion farmaceutica oftalmica, compuestos antimicrobianos a base de carbolina | |
| AR120652A1 (es) | Antagonistas de sstr5 | |
| AR119082A1 (es) | Compuestos de pirazol disustituidos | |
| AR129054A1 (es) | Inhibidores de la proteína tirosina fosfatasa y usos de estos | |
| AR123357A1 (es) | Compuestos y métodos para el tratamiento de infecciones virales | |
| AR098583A1 (es) | Compuesto de sulfonamida de benzotiofeno, composición farmacéutica que lo comprende y su uso para la preparación de dicha composición |